论文部分内容阅读
目的:观察肾康丸对糖尿病肾病(DN)大鼠氧自由基(OFR)代谢的影响,探讨其治疗DN的机制。方法:应用链脲佐菌素建立大鼠DN模型,将DN模型大鼠随机分为4组:DN模型对照组、肾康丸组、厄贝沙坦组、肾康丸和厄贝沙坦合用组;另设正常对照组。各组分别干预8 w后,观察肾组织中丙二醛(MDA)含量和谷胱甘肽过氧化物酶(GSH-Px)、过氧化氢酶(CAT)、铜锌超氧化物歧化酶(Cu,Zn-SOD)活性的变化,RT-PCR法检测肾组织GSH-Px、CAT、Cu,Zn-SOD mRNA的表达。结果:应用肾康丸、厄贝沙坦干预后,DN大鼠肾组织中MDA含量显著减少,GSH-Px、CAT、Cu,Zn-SOD活性显著增加,GSH-Px与Cu,Zn-SOD mRNA表达水平均显著降低,CAT mRNA表达水平变化无显著性差异,肾康丸和厄贝沙坦合用组效果更为显著。结论:肾康丸对DN的肾保护作用与减少OFR的生成、抑制氧化应激有关,且与血管紧张素Ⅱ受体拮抗剂厄贝沙坦合用具有协同作用。
Objective: To observe the effects of Shenkang Pill on metabolism of oxygen free radical (OFR) in diabetic nephropathy (DN) rats and to explore its mechanism of DN treatment. Methods: DN model was established by streptozotocin (STZ). The DN model rats were randomly divided into 4 groups: DN model control group, Shenkangwan group, irbesartan group, Shenkangwan and irbesartan group Another set of normal control group. After intervention for 8 weeks in each group, the contents of malondialdehyde (MDA), glutathione peroxidase (GSH-Px), catalase (CAT), copper and zinc superoxide dismutase Cu, Zn-SOD) were detected by RT-PCR. The expression of GSH-Px, CAT, Cu, Zn-SOD mRNA in renal tissue was detected by RT-PCR. Results: After treated with Shenkang Pills and Irbesartan, the content of MDA in the kidney of DN rats decreased significantly, and the activities of GSH-Px, CAT, Cu and Zn-SOD increased significantly The level of expression was significantly reduced, CAT mRNA expression levels showed no significant difference, Shen Kang Wan and irbesartan combination group effect is more significant. CONCLUSION: The renal protective effect of Shenkang Pill on DN is related to the reduction of OFR production and inhibition of oxidative stress, and synergistic effect with irbesartan in combination with angiotensin Ⅱ receptor antagonist.